Excedrin for “first-line” treatment
This article was originally published in The Tan Sheet
Executive Summary
Novartis is promoting Excedrin Migraine as "evidence-based medicine for the first-line treatment of migraine," according to a new print ad published in the May 24 issue of The Journal of the American Medical Association. As part of the firm's "First Line at the First Sign" advertising push, the ad includes statements such as, "clinically proven to provide early and powerful relief" and "statistically significant pain reduction seen as early as 30 minutes." The ad shows a bottle of Excedrin Migraine bursting through a doctor's prescription pad and states, "Powerful migraine efficacy with OTC convenience and safety." The UK's health body recently approved behind-the-counter sale of GlaxoSmithKline's Imigran Recovery (sumatriptan 50 mg) for migraine (1"The Tan Sheet" May 22, 2006, p. 3)...
You may also be interested in...
GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale
GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.